Cipla, Pfizer and DRL among 66 drug firms that fail quality test

Published On 2017-07-23 04:22 GMT   |   Update On 2017-07-23 04:22 GMT

Some of Major drug companies like Pfizer, Alembic Pharma, Cipla, Dr Reddy’s Laboratories & Zydus Healthcare are among 66 drug companies that have failed the test for Not of Standard Quality (NSQ) drugs, according to a report released by CDSCO.


In a bid to bring down the proportion of its substandard drugs to 2% over the next three years to match global standards, National Institute of Biologicals was deputed by Ministry of Health and Family Welfare to conduct the National Drug Survey across the country. The institute was asked to check and ascertain the proportion of drug samples failing in Quality testing and tabulate them.


The survey, conducted to check the proportion of substandard drugs in the country, had tested 47,012 samples from 1,719 manufacturing units, CDSCO said. Around 3.16% of these samples were found to be not of standard quality. The estimated percentage of NSQ drugs from government sources was 10.02% and the percentage of spurious drugs was 0.05%. Globally, the acceptable rate is around 2%.


Joint Secretary (Regulation), Ministry of Health & Family Welfare in general review meeting about CDSCO, held on 06.07.2017 decided that the list of drug manufacturers where more than five samples have been failed, be put on CDSCO Website separately.


Accordingly the report was displayed which states that Pfizer has failed the test for 25 samples, Dr Reddy’s Laboratories and Alembic have 9 NSQ samples each. In addition to this seven samples of Cipla, and six samples of Zydus Healthcare have failed the government’s test.


Find the attachment for the same.


http://www.cdsco.nic.in/writereaddata/National%20Drug%20Survey.pdf

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News